Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JUNO THERAPEUTICS INC

SummaryNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JUNO THERAPEUTICS, INC. Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders

01/22/2018 | 01:54pm EDT

Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Juno Therapeutics, Inc. (“Juno”) (NASDAQ: JUNO) concerning the acquisition by Celgene Corporation. Under the terms of the agreement, Juno shareholders will only receive $87.00 per Juno share owned. The consideration is significantly lower than at least one analyst’s estimated value of $98.00.

If you are an affected investor, and you want to learn more about the investigation or if you have information that you believe would be helpful to our investigation of the fairness of the proposed transaction, contact Willie Briscoe at The Briscoe Law Firm, PLLC via email at shareholders@thebriscoelawfirm.com or by calling (888) 809-2750. There is no cost or fee to you.

The investigation centers on whether Juno’s Board of Directors is acting in the shareholders’ best interests, whether the board considered alternatives to the acquisition, and whether the board has employed an adequate process to review and act on the proposed transaction. Notably, at least one analyst with Yahoo! Finance believes the true inherent value of Juno could be as high as $98.00 per share.

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation matters, including claims of investor and stockholder fraud, shareholder derivative suits, and securities class actions.


ę Business Wire 2018
All news about JUNO THERAPEUTICS INC
2018Merits of any Takeda bid for Shire questioned, shares slide
RE
2018Merits of any Takeda bid for Shire questioned, shares slide
RE
2018Drugmaker Shire soars as Japan's Takeda considers bid
RE
2018Sangamo in $3 billion gene-editing deal with Gilead
RE
2018JUNO THERAPEUTICS : Celgene Receives Antitrust Clearance for Juno Acquisition
BU
2018Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
2018THE LAW OFFICES OF VINCENT WONG : Reminds Investors of an Investigation of Juno Therapeuti..
BU
2018THE LAW OFFICES OF VINCENT WONG : Notifies Investors of an Investigation of Juno Therapeut..
BU
2018WEISSLAW LLP : Investigates Juno Therapeutics Inc. Acquisition
PR
2018Rigrodsky & Long, P.A. Announces Investigation of Juno Therapeutics, Inc. Buyout
BU
More news
Analyst Recommendations on JUNO THERAPEUTICS INC
More recommendations
Managers and Directors
Mark J. Gilbert Chief Medical Officer & Senior Vice President
Ann L. Lee Executive Vice President-Technical Operations
Mark J. Alles Director
Peter N. Kellogg Director
Nicole Keith Investor Relations Contact
Sector and Competitors
1st jan.Capi. (M$)
JUNO THERAPEUTICS INC90.24%0
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156